For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination r ...

The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...

If you purchased or acquired securities in ESSA Pharma between December 12, 2023 and October 31, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at ...

Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...

Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

Opens in a new tab or window SAN FRANCISCO -- The addition of radionuclide therapy with 177 Lu-PSMA-617 (Pluvicto) to enzalutamide (Xtandi) improved overall survival (OS) in patients with ...

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

NEW YORK, NY / ACCESS Newswire / February 21, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ESSA Pharma Inc. (NASDAQ:EPIX) between December 12, ...